QUOTE AND NEWS
Sydney Morning Herald  Aug 23  Comment 
Acrux has increased full year profit by 23 per cent as the biotechnology firm started to receive payments for its underarm testosterone booster.
The Australian  May 27  Comment 
AUSTRALIAN biotech company Acrux has been granted marketing approval in Sweden for a spray-on menopause treatment.
Sydney Morning Herald  Mar 16  Comment 
THE local junior biotech Acrux could rake in more than $US335 million from the commercialisation and sale of its novel underarm testosterone treatment for men following a global licensing deal with the pharmaceutical giant Eli Lilly.
BusinessWeek  Mar 16  Comment 
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Sydney Morning Herald  Mar 16  Comment 
Acrux Ltd has entered into a licence agreement with Eli Lilly and Company for Eli Lilly to commercialise Acrux's underarm testosterone solution, Axiron.
Bloomberg  Mar 15  Comment 
(Update1) Eli Lilly & Co., the maker of the impotence pill Cialis, acquired from Acrux Limited a license to commercialize an underarm testosterone lotion for men whose low levels of the hormone leave them with limited sex drive.
StreetInsider.com  Mar 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Eli+Lilly+%28LLY%29+and+Acrux+Enter+into+AXIRON+Worldwide+License+and+Commercialization+Agreement/5439423.html for the full story.
FierceBiotech  Sep 29  Comment 
Australia's Acrux has lived up to analysts' expectations, reporting that its late-stage trial of a new testosterone spray proved promising, which clears the way to an FDA application later this year. Acrux's share price has tripled this year as...
Bloomberg  Sep 29  Comment 
(Update1) An experimental treatment for men with low testosterone improved sex drive and erections in a late-stage patient study, the product’s Australian developer Acrux Ltd. said today.





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki